An Overview of COVID-19: Focus on Pharmacological Aspect
暂无分享,去创建一个
Nandhini Saravanabavan | Padmavathi Shanmuganathan | Manimekalai Kumarappan | Kartik J Salwe | Barathane Datchanamurthy | Johan Pandian | R. Sudar Codi | Vimala Ananthy | Kamalasundar Thanuskodi | Uma Narayanamurthy | Vimala Ananthy | K. Salwe | N. Saravanabavan | Padmavathi Shanmuganathan | Manimekalai Kumarappan | Uma Narayanamurthy | Barathane Datchanamurthy | R. S. Codi | J. Pandian | Kamalasundar Thanuskodi
[1] N. Bashir,et al. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses , 2020, Journal of Advanced Research.
[2] W. Ko,et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.
[3] Jindrich Cinatl,et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus , 2004, Biochemical and Biophysical Research Communications.
[4] P. Barnes,et al. Nitric oxide and airway disease. , 1995, Annals of medicine.
[5] Zhenghong Yuan,et al. Interferon priming enables cells to partially overturn the SARS coronavirus-induced block in innate immune activation. , 2009, The Journal of general virology.
[6] Lisa E. Gralinski,et al. Return of the Coronavirus: 2019-nCoV , 2020, Viruses.
[7] A. Jadad,et al. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19 , 2020, JMIRx med.
[8] L. Saif. Animal coronaviruses: what can they teach us about the severe acute respiratory syndrome? , 2004, Revue scientifique et technique.
[9] R. Baric,et al. Zn2+ Inhibits Coronavirus and Arterivirus RNA Polymerase Activity In Vitro and Zinc Ionophores Block the Replication of These Viruses in Cell Culture , 2010, PLoS pathogens.
[10] A. Al-Osail,et al. The history and epidemiology of Middle East respiratory syndrome corona virus , 2017, Multidisciplinary Respiratory Medicine.
[11] Xiaotao Lu,et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.
[12] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[13] S. Perlman,et al. ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway Epithelia , 2005, Journal of Virology.
[14] B. Willms,et al. Efficacy of thioctic acid in the therapy of peripheral diabetic neuropathy. , 1980, Hormone and metabolic research. Supplement series.
[15] Shibo Jiang,et al. Recent advances in the detection of respiratory virus infection in humans , 2020, Journal of medical virology.
[16] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[17] Jing Zhao,et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.
[18] Weier Wang,et al. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China , 2020, Journal of medical virology.
[19] C. Midgley,et al. Middle East Respiratory Syndrome Coronavirus Infection Dynamics and Antibody Responses among Clinically Diverse Patients, Saudi Arabia , 2019, Emerging infectious diseases.
[20] B. Fielding,et al. Coronavirus envelope protein: current knowledge , 2019, Virology Journal.
[21] S. Sawicki,et al. Coronavirus Transcription: A Perspective , 2005, Current topics in microbiology and immunology.
[22] R. Hilgenfeld. From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design , 2014, The FEBS journal.
[23] Jindrich Cinatl,et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.
[24] Z. Cao,et al. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses , 2011, Peptides.
[25] Guangdi Li,et al. Therapeutic options for the 2019 novel coronavirus (2019-nCoV) , 2020, Nature Reviews Drug Discovery.
[26] Catharine I Paules,et al. Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.
[27] V. Misra,et al. Bats and Coronaviruses , 2019, Viruses.
[28] Jie Dong,et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study , 2020, Chinese medical journal.
[29] Malik Peiris,et al. Middle East respiratory syndrome , 2015, The Lancet.
[30] E. Collisson,et al. Chicken interferon type I inhibits infectious bronchitis virus replication and associated respiratory illness. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[31] Qianyun Liu,et al. Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.
[32] M. Kikkert,et al. Host Factors in Coronavirus Replication , 2017, Current topics in microbiology and immunology.
[33] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[34] I Rovira,et al. Nitric oxide , 2021, Reactions Weekly.
[35] Xiaolong Qi,et al. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia , 2020, Radiology.
[36] D. Veesler,et al. Structural insights into coronavirus entry , 2019, Advances in Virus Research.
[37] N. Seidah,et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread , 2005, Virology Journal.
[38] Peter Cameron,et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.
[39] J. Bussel,et al. Uses of intravenous gammaglobulin in immune hematologic disease. , 1995, Immunological investigations.
[40] Yan Zhao,et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version) , 2020, Military Medical Research.
[41] H. Ho,et al. Glucose-6-Phosphate Dehydrogenase Deficiency Enhances Human Coronavirus 229E Infection , 2008, The Journal of infectious diseases.
[42] David Shum,et al. Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs , 2020, Antimicrobial Agents and Chemotherapy.
[43] V. A. Maksimov,et al. [Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures]. , 2008, Voprosy virusologii.
[44] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[45] Yunhui Liu,et al. Potential interventions for novel coronavirus in China: A systematic review , 2020, Journal of medical virology.
[46] P. Hawkey,et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.
[47] J. Baillie,et al. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.
[48] E. Won,et al. Combination Therapy with Lopinavir/Ritonavir, Ribavirin and Interferon-α for Middle East Respiratory Syndrome , 2015, Antiviral therapy.
[49] G. Kroemer,et al. Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses , 2020, Cell stress.
[50] C. Meschievitz,et al. Prevention of Experimental Coronavirus Colds with Intranasal α-2b Interferon , 1986, The Journal of infectious diseases.
[51] D. Wang,et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.
[52] B. Medhi,et al. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach , 2020, Indian journal of pharmacology.
[53] M. Dayer,et al. Lopinavir; A Potent Drug against Coronavirus Infection: Insight from Molecular Docking Study , 2017 .
[54] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[55] S. Hewitt,et al. Neuraminidase inhibitors for treatment of influenza A and B infections. , 1999, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[56] D. Tai. Pharmacologic treatment of SARS: current knowledge and recommendations. , 2007, Annals of the Academy of Medicine, Singapore.
[57] R. Rossaint,et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. , 1995, Chest.
[58] Andrea Marzi,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[59] B. Medhi,et al. Drug targets for corona virus: A systematic review , 2020, Indian journal of pharmacology.
[60] Z. Rao,et al. Drug design targeting the main protease, the Achilles' heel of coronaviruses. , 2006, Current pharmaceutical design.
[61] A. Phelan,et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease , 2020, The Lancet.
[62] Z. Memish,et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option , 2020, The Lancet.
[63] Chung-ke Chang,et al. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein , 2015, Drug Discovery Today.
[64] Ralph S. Baric,et al. Recombination, Reservoirs, and the Modular Spike: Mechanisms of Coronavirus Cross-Species Transmission , 2009, Journal of Virology.
[65] G. Whittaker,et al. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein , 2012, Viruses.
[66] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.